肺癌脑转移252例综合治疗临床分析  

Clinical analysis of combination therapy for 252 patients of lung cancer with brain metastasis

作　　者：张树才[1] 杨新杰[1] 赵爱国 胡范斌 马玙[1] 王群会[1] 

机构地区：[1]北京市结核病胸部肿瘤研究所,101149 [2]河南濮阳市结核病防治所

出　　处：《中华结核和呼吸杂志》1999年第8期475-477,共3页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：目的　探讨肺癌脑转移综合治疗的疗效及预后影响因素。方法　回顾性分析了１９９０年１ 月～１９９６ 年１２ 月采用不同方法治疗的２５２ 例肺癌脑转移患者生存期与生存率。结果　转移灶手术切除及γ或 Ｘ刀治疗辅以放疗、化疗以及放疗与化疗联合组的中位生存期及１ 、２ 年生存率明显高于单纯放疗与化疗组（ Ｐ＜ ００１ 及 Ｐ＜ ００５） ，肺癌的病理类型对生存期与生存率无明显影响（ Ｐ＞００５） ；单发转移及无颅外转移者生存期（ 中位生存期分别为８５ 和８５ 个月） 与生存率（１ 年生存率分别为３５ ％ 和２９ ％ ，２ 年生存率分别为１１ ％ 和８ ％ ） 明显高于多发转移及伴颅外血行转移者（ Ｐ＜ ００１） ；高年龄者（ ≥５０ 岁）１ 年生存率（２９ ％ ） 明显高于低年龄组（１５ ％ ， Ｐ＜ ００５） 。结论　转移灶的手术切除及γ或 Ｘ刀治疗加放疗和化疗是治疗肺癌脑转移患者的首选方法，转移的数量与部位多少及年龄是影响预后的因素。Objective To evaluate the efficacy of combination therapy and prognostic factors for lung cancer patients with brain metastasis. Methods The survival time and survival rates with various therapeutic methods were analyzed retrospectively in 252 patients with brain metastasis Results The median survival time and 1,2 year survival rates in surgery and X knife plus radio chemotherapy group and combination therapy of radiotherapy with chemotherapy were significantly longer than radio chemotherapy alone group ( P <0 01 and P <0 05); the pathological type of lung cancer did not affect the survival time and survival rate ( P >0 05); the survival time and survival rate of single brain metastasis (median survival time was 8 5 months 1,2 year survival rates were 35% and 11% respectively) and non extrabrain metastasis (8 5 months, 29%, 8%) were much longer than multiple brain metastasis and extrabrain metastasis ( P <0 01); the 1 year survival rate of older patients(≥50 years,29%) were significantly higher than younger ones (<50 years, 15%) ( P <0 05) Conclusions Combination therapy of surgery and X knife plus radio chemotherapy are better than radio chemotherapy alone for brain metastasis of lung cancer, severity of metastasis and patients′ age are the prognostic factors

关 键 词：肺肿瘤 肿瘤转移 脑转移瘤 综合疗法 

分 类 号：R734.205[医药卫生—肿瘤] R739.410.5[医药卫生—临床医学]